- Third quarter revenue for the acquired businesses was $8.2 million in line with expectations.
- The installed base of XTRAC systems in the U.S. expanded to 698 systems, up from 590 at the end of the third quarter 2014, as reported to us by PhotoMedex.
- Achieved positive non-GAAP adjusted income in first full quarter of combined operations. See Non-GAAP Measures below.
- Integration of the acquired businesses into MELA is essentially complete.
HORSHAM, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today reported financial results for the third quarter ended September 30, 2015. Third Quarter and Recent Corporate Highlights